PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis ; volume:11 ; number:2 ; day:5 ; month:12 ; year:2013 ; pages:1-2 ; date:12.2013
Pediatric rheumatology ; 11, Heft 2 (5.12.2013), 1-2, 12.2013
- Classification
-
Medizin, Gesundheit
- Creator
-
Anink, J.
Otten, MH
Van Suijlekom-Smit, LA
Van Rossum, MA
Dolman, KM
Hoppenreijs, EP
Ten Cate, R.
Vogl, T.
Foell, D.
Roth, J.
Holzinger, D.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-11-S2-P157
- URN
-
urn:nbn:de:101:1-2019060907102216298412
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Anink, J.
- Otten, MH
- Van Suijlekom-Smit, LA
- Van Rossum, MA
- Dolman, KM
- Hoppenreijs, EP
- Ten Cate, R.
- Vogl, T.
- Foell, D.
- Roth, J.
- Holzinger, D.
- SpringerLink (Online service)
Other Objects (12)
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept